Categories
Change Password!
Reset Password!
In premenopausal females with adenomyosis, trimonthly use of 10.8 mg Goserelin has comparable efficacy to monthly dose of 3.6 mg Goserelin and is non-inferior in terms of tolerability and safety.
In premenopausal women having symptomatic adenomyosis, both single trimonthly (10.8 mg) and monthly (3.6 mg) administration of goserelin for three months considerably relieved dysmenorrhea symptoms, decreased uterine volume, improved anemia, and minimized CA125 levels, according to a prospective cohort study. In premenopausal patients suffering from adenomyosis, the clinical effectiveness and safety of Goserelin taken trimonthly versus Goserelin received monthly were compared by researchers.
A total of 139 females who reported either menorrhagia or dysmenorrhea were enrolled. Participants were segregated to receive either single subcutaneous injection of goserelin 10.8 mg (n = 70) or monthly subcutaneous goserelin 3.6 mg (n = 69) for three months. After 12 weeks, a follow-up visit was performed at the outpatient department.
Overall, 130 individuals, incorporating 68 and 62 subjects respectively in the Goserelin 10.8 mg (n = 70) and 3.6 mg (n = 69) groups finished the study. In both the intervention groups, a considerable rise in hemoglobin levels and a substantial decline in the cancer antigen 125 (CA125) values, uterine volume, and dysmenorrhea (Numerical Rating Scale [NRS]) score were observed. The two groups did not considerably differ from one another. Compared to the 10.8 mg group, the sum of adverse event scores was somewhat greater in the Goserelin 3.6 mg group.
Therefore, trimonthly 10.8 mg Goserelin appears to be an alternative regimen that is more convenient for premenopausal females with adenomyosis, potentially aiding to improve compliance. Furthermore, it is less expensive and effective in minimizing patient outpatient visits, that will aid to decrease patient-associated medical care costs and clinician burden on physicians.
Gynecological Endocrinology
Clinical efficacy and safety of trimonthly administration of Goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study
Hao Sun et al.
Comments (0)